Newer methods of hormonal therapy for prostate cancer.

M. S. Soloway

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4% complete remissions, 32% partial remissions, and 40% stable) using National Prostatic Cancer Project criteria.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
Issue number5 Suppl
StatePublished - Nov 1 1984

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Newer methods of hormonal therapy for prostate cancer.'. Together they form a unique fingerprint.

Cite this